scholarly journals Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study

2012 ◽  
Vol 15 (4) ◽  
pp. 397-401 ◽  
Author(s):  
T Koie ◽  
C Ohyama ◽  
H Yamamoto ◽  
S Hatakeyama ◽  
T Yoneyama ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Luteinizing Hormone ◽  
Low Dose ◽  
Estramustine Phosphate ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: A single-center study.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e542-e542
Author(s):  
Kazuhisa Hagiwara ◽  
Takuya Koie ◽  
Yuki Tobisawa ◽  
Hayato Yamamoto ◽  
Atsushi Imai ◽  
...  
Keyword(s):  
High Risk ◽  
Biochemical Recurrence ◽  
Low Dose ◽  
Gnrh Antagonist ◽  
Gonadotropin Releasing Hormone ◽  
Lhrh Agonist ◽  
Estramustine Phosphate ◽  
Releasing Hormone ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

e542 Background: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) for high-risk Pca patients treated with neoadjuvant therapy comprising a luteinizing hormone-releasing hormone agonist plus low-dose estramustine (LHRH agonist + EMP) prior to radical prostatectomy (RP). In the present study, we evaluated the efficacy of neoadjuvant therapy comprising a gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate (GnRH antagonist + EMP) in patients with high-risk Pca. Methods: Between September 2005 and March 2016, we identified 406 high-risk Pca patients of whom 136 received neoadjuvant GnRH antagonist + EMP and 270 received LHRH agonist + EMP before RP. We retrospectively evaluated the clinical and pathological covariates between the two groups. The primary endpoint was the rate of pathological ≤ T2 status, and the secondary endpoint was BRFS. Results: The rates of pathological ≤ T2 status were 80.2% and 61.5% in the GnRH antagonist + EMP and LHRH agonist + EMP groups, respectively ( P < 0.001). The 3-year BRFS rates were 97.8% and 85.2% in the GnRH antagonist + EMP and LHRH agonist + EMP groups, respectively ( P = 0.021). Multivariate analysis revealed that biopsy Gleason score, GnRH antagonist + EMP, and clinical T stage were independent predictors of pathological ≤ T2 status in surgical specimens. Conclusions: Our findings suggest that neoadjuvant GnRH antagonist + EMP followed by RP may improve the pathological outcomes and reduce the risk of biochemical recurrence in patients with high-risk Pca. Further prospective studies to confirm these findings are warranted.

Degarelix as a neoadjuvant hormonal therapy for acute urinary tract toxicity associated with external beam radiotherapy for intermediate- and high-risk prostate cancer: a propensity score matched analysis

2020 ◽  
Author(s):  
Shinro Hata ◽  
Toshitaka Shin ◽  
Satoki Abe ◽  
Kaori Kawano ◽  
Ryuta Sato ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
High Risk ◽  
Luteinizing Hormone ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
High Risk Prostate Cancer ◽  
Hormone Antagonists

Abstract Background In prostate cancer treatment, lower urinary tract symptoms significantly improve with luteinizing hormone-releasing hormone antagonists use compared with agonists. However, it is unclear whether luteinizing hormone-releasing hormone antagonists can decrease acute urinary tract toxicity during external beam radiotherapy. This study aimed to assess whether luteinizing hormone-releasing hormone antagonists used as neoadjuvant therapy reduced acute urinary tract toxicity during external beam radiotherapy compared with luteinizing hormone-releasing hormone agonists. Methods The study included 78 patients who underwent intensity-modulated radiation therapy for intermediate- and high-risk prostate cancer between April 2013 and January 2020. Irradiation was initiated after 3–6 months of neoadjuvant therapy. Androgen deprivation therapy was given to the intermediate-risk group for 6 months and the high-risk group for 2–3 years. The European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group toxicity grading scale was used to evaluate the urinary tract system toxicity. Relevant clinical factors were used in matching patients based on propensity scores to enable comparison between the groups. Results Each group had 27 matched patients. There was no reduction in urinary tract toxicity with the use of luteinizing hormone-releasing hormon antagonists (P = 0.624). For patients with an International Prostate Symptom Score of ≥11 at the start of treatment, 18 patients in each group were matched. Significantly lower scores were observed in the luteinizing hormone-releasing hormon antagonist group (P = 0.041). Conclusions Luteinizing hormone-releasing hormon antagonists may reduce acute urinary tract toxicity during prostate cancer external beam radiotherapy compared with luteinizing hormone-releasing hormon agonists, in particular in patients with moderate to severe symptoms at the start of treatment.

Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach

2020 ◽  
Vol 32 (7) ◽  
pp. e162
Author(s):  
C. Mikropoulos ◽  
S. Otter ◽  
C. Perna ◽  
S. Khaksar ◽  
A. Franklin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Dose Rate ◽  
Low Dose ◽  
Evidence Based ◽  
Low Dose Rate ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Brachytherapy Boost ◽  
Low Dose Rate Brachytherapy
Sign in / Sign up

Export Citation Format

Share Document